[ad_1] R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion […]
Tag: Rigel Pharmaceuticals
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
[ad_1] SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior […]
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
[ad_1] First trial in Rigel’s multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel’s targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, […]
